[Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
The authors have tested a new preparation of dihydroergotamine (microgranules in a capsule) by comparing the clinical results obtained in 30 patients suffering from morning migraine with the plasma levels of the active substance measured in 8 healthy subjects. The microgranules were administered in doses of 30 mg/24 hours and compared with a similar dose of a dihydroergotamine solution. The close correlation observed between sustained plasma levels and prolonged therapeutic effects indicates a truly programmed delivery of dihydroergotamine by the microgranule preparation.
D000293:Adolescent; D000328:Adult; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D012996:Solutions
D003692:Delayed-Action Preparations; D012996:Solutions; D004087:Dihydroergotamine
Le traitement des migraines matinales. Corrélation clinique et biocinétique d'une dihydroergotamine à libération programmée.